| Literature DB >> 28928898 |
Yuan Shen1,2, Hui Guo3, Tao Wu3, Qiang Lu1,4, Ke-Jun Nan3, Yi Lv1,4, Xu-Feng Zhang1,4.
Abstract
Understanding the ways in which socioeconomic status affects prognosis of hepatocellular carcinoma (HCC) is important for building up strategies eliminating the inequalities in cancer diagnosis and treatments among different groups, which, remains undetermined. In the present study, 1485 newly diagnosed HCC patients with complete demographic and clinical data were included. Socioeconomic data, including education, annual household income and residency was also reported by patients or families. In the present study, less educated patients were older, more female involved, poorly paid, more living in rural places, had more advanced tumor burden, received less curative and loco-regional therapies, and thus showed poorer short-term and long-term outcomes (in total or after surgical resection) than the highly educated. Patients with lower income were less educated, less treated, and more likely to live in rural places, had more advanced stages of HCC and thus poorer long-term survival (in total or after surgical resection) than higher income groups. In Cox regression analysis, lower household income was independently associated with poorer outcome (HR=1.2, 95% CI: 1.0-1.4, p=0.036). These results indicate that education and income are critically associated with early diagnosis, treatments and prognosis of HCC. Much more efforts should be taken to support the patients with less education and lower income to improve the outcomes of HCC.Entities:
Keywords: Hepatocellular carcinoma; education; income; surgery; survival.
Year: 2017 PMID: 28928898 PMCID: PMC5604458 DOI: 10.7150/jca.19922
Source DB: PubMed Journal: J Cancer ISSN: 1837-9664 Impact factor: 4.207
Demographic and treatments of the patients at different education level
| Variables | Below high school | High school level | Above high school | P value |
|---|---|---|---|---|
| Age (years) | 57±111,2;1,3 | 54±12 | 55±14 | <0.001 |
| Male gender | 192 (71.4%)1,2; 1,3 | 744 (82.5%) | 269 (85.7%) | <0.001 |
| Child-Pugh class | 0.204 | |||
| A | 232 (8.6%) | 799 (8.9%) | 263 (8.4%) | |
| B | 32 (11.9%) | 92 (10.2%) | 47 (15.0%) | |
| C | 5 (1.9%) | 11 (1.2%) | 4 (1.3%) | |
| Household income* | 1,2; 1,3 | 2,3 | <0.001 | |
| ≤ 50,000 CNY | 136 (50.6%) | 189 (10.9%) | 15 (4.8%) | |
| 50,000-200,000 CNY | 110 (40.9%) | 529 (58.6%) | 123 (39.2%) | |
| >200,000 CNY | 20 (7.4%) | 178 (19.7%) | 176 (56.1%) | |
| Residence | 1,2; 1,3 | 2,3 | <0.001 | |
| Rural/small urban | 221 (82.2%) | 434 (48.1%) | 27 (8.6%) | |
| Large urban | 48 (17.8%) | 468 (51.9%) | 287 (91.4%) | |
| Hepatitis status | 1,3 | 0.021 | ||
| Hepatitis B/C | 192 (71.4%) | 705 (78.2%) | 253 (80.5%) | |
| None | 77 (28.6%) | 197 (21.8%) | 61 (19.4%) | |
| First Dept. admitted | 0.408 | |||
| Surgery Dept. | 166 (61.7%) | 690 (76.5%) | 260 (82.8%) | |
| Internal Medical Dept. | 91 (33.8%) | 198 (22.0%) | 50 (15.9%) | |
| Other Dept. | 12 (4.5%) | 14 (15.5%) | 4 (1.3%) | |
| BCLC stages | 1,3 | 2,3 | 0.027 | |
| 0-A | 105 (39.0%) | 336 (37.3%) | 144 (45.9%) | |
| B-D | 164 (61.0%) | 566 (62.7%) | 170 (54.1%) | |
| Primary treatments | 1,2; 1,3 | 2,3 | <0.001 | |
| Liver transplant | 2 (0.7%) | 15 (1.7%) | 17 (5.4%) | |
| Surgical resection | 117 (43.5%) | 384 (42.6%) | 122 (38.9%) | |
| Locoregional therapies | 117 (43.5%) | 437 (48.4%) | 148 (47.1%) | |
| Supportive treatments | 33 (12.3%) | 66 (7.3%) | 27 (8.6%) | |
| 30-day mortality | 16 (5.9%) | 47 (5.2%) | 12 (3.8%) | 0.475 |
| 90-day mortality | 39 (14.5%)1,2;1,3 | 88 (9.8%) | 28 (8.9%) | 0.045 |
* Data unavailable in 9 patients; BCLC, Barcelona Liver Cancer; CNY, Chinese Yuan (1 CNY≈0.146 USD); 1,2 p<0.05 when compared between group 1 and 2; 1,3 p<0.05 when compared between group 1 and 3; 2,3 p<0.05 when compared between group 2 and 3.
Demographic and treatments of the 1476 patients with different household income
| Variables | Low income | Moderate income | High income | P value |
|---|---|---|---|---|
| Age (years) | 55±12 | 54±122,3 | 56±13 | 0.020 |
| Male gender | 270 (79.4%) | 625 (82.0%) | 303 (81.0%) | 0.590 |
| Child-Pugh class | 1,3 | 2,3 | <0.001 | |
| A | 309 (90.9%) | 672 (88.2%) | 304 (81.3%) | |
| B | 28 (8.2%) | 77 (10.1%) | 66 (17.6%) | |
| C | 3 (0.8%) | 13 (1.7%) | 4 (1.1%) | |
| Residence | 1,2; 1,3 | 2,3 | <0.001 | |
| Rural/small urban | 236 (69.4%) | 334 (43.8%) | 103 (27.5%) | |
| Large urban | 104 (30.6%) | 428 (56.2%) | 271 (72.5%) | |
| Hepatitis status | 0.083 | |||
| Hepatitis B/C | 249 (73.3%) | 595 (78.0%) | 299 (80.0%) | |
| Others | 91 (26.8%) | 167 (21.9%) | 75 (20.1%) | |
| First Dept. admitted | 0.449 | |||
| Surgery Dept. | 235 (69.1%) | 564 (74.0%) | 308 (82.4%) | |
| Internal Medical Dept. | 98 (28.8%) | 183 (24.0%) | 58 (15.5%) | |
| Other Dept. | 7 (2.1%) | 15 (2.0%) | 8 (2.1%) | |
| BCLC stages | 1,2; 1,3 | 0.001 | ||
| 0-A | 105 (30.9%) | 310 (40.7%) | 165 (44.1%) | |
| B-D | 235 (69.1%) | 452 (59.3%) | 209 (55.9%) | |
| Primary treatments | 0.081 | |||
| Liver transplant | 2 (0.6%) | 19 (2.5%) | 13 (3.5%) | |
| Surgical resection | 150 (44.1%) | 312 (41.0%) | 154 (41.1%) | |
| Locoregional therapies | 151 (44.4%) | 369 (48.4%) | 180 (48.1%) | |
| Supportive treatments | 37 (10.9%) | 62 (8.1%) | 27 (7.2%) | |
| 30-day mortality | 26 (7.6%)1,2;1,3 | 33 (4.3%) | 16 (4.3%) | 0.049 |
| 90-day mortality | 44 (12.9%) | 79 (10.4%) | 32 (8.6%) | 0.159 |
BCLC, Barcelona Liver Cancer; 1,2 p<0.05 when compared between group 1 and 2; 1,3 p<0.05 when compared between group 1 and 3; 2,3 p<0.05 when compared between group 2 and 3.
Figure 1A, overall survival of 1485 patients with hepatocellular carcinoma (HCC) at different education level; B, overall survival of 1476 HCC patients with different annual household income; C, overall survival of 1485 HCC patients living in rural areas and city.
Figure 2A, overall survival of 623 patients at different education level undergoing surgical resection hepatocellular carcinoma (HCC); B, overall survival of 616 patients with different household income after surgical resection for HCC; C, overall survival of 623 patients living rural areas and city after surgical resection for HCC.
Univariate and multivariate analysis of the risk factors of survival for hepatocellular carcinoma
| Variables | events | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |||
| Age (years) | ||||||
| ≤ 50 | 560 | 307 | 1 | |||
| > 50 | 925 | 561 | 1.1 (1.0-1.3) | 0.070 | ||
| Gender | ||||||
| Female | 280 | 159 | 1 | |||
| Male | 1205 | 709 | 1.0 (0.8-1.2) | 0.782 | ||
| Child-Pugh class | ||||||
| A | 1294 | 733 | 1 | 1 | ||
| B/C | 191 | 135 | 1.9 (1.5-2.2) | <0.001 | 1.6 (1.3-1.9) | <0.001 |
| Education | ||||||
| Above high school | 314 | 168 | 1 | 1 | ||
| High school level | 902 | 537 | 1.2 (1.0-1.4) | 0.031 | 1.2 (0.9-1.5) | 0.217 |
| Below high school | 269 | 163 | 1.3 (1.1-1.7) | 0.007 | 1.2 (1.0-1.4) | 0.118 |
| Residence | ||||||
| Rural/small urban | 682 | 401 | 1.1 (0.9-1.2) | 0.349 | ||
| Large urban | 803 | 467 | 1 | |||
| Household income | ||||||
| >200,000 CNY | 374 | 211 | 1 | 1 | ||
| 50,000-200,000 CNY | 762 | 443 | 1.3 (1.1-1.5) | 0.004 | 1.2 (1.0-1.4) | 0.069 |
| ≤ 50,000 CNY | 340 | 210 | 1.4 (1.2-1.7) | 0.001 | 1.2 (1.0-1.4) | 0.036 |
| Tumor size | ||||||
| < 5 cm | 808 | 448 | 1 | 1 | ||
| ≥ 5 cm | 677 | 420 | 1.3 (1.2-1.5) | <0.001 | 1.1 (0.8-1.3) | 0.507 |
| Tumor number | ||||||
| ≤ 3 | 1296 | 750 | 1 | |||
| > 3 | 189 | 118 | 1.2 (0.9-1.4) | 0.157 | ||
| Portal vein thrombosis | ||||||
| No | 1176 | 678 | 1 | 1 | ||
| Yes | 309 | 190 | 1.2 (1.0-1.4) | 0.048 | 1.1 (0.7-1.6) | 0.084 |
| BCLC stages | ||||||
| 0-A | 585 | 305 | 1 | 1 | ||
| B | 542 | 330 | 1.4 (1.2-1.6) | <0.001 | 2.6 (1.6-4.3) | <0.001 |
| C | 318 | 203 | 1.5 (1.3-1.8) | <0.001 | 2.8 (1.6-4.9) | <0.001 |
| D | 40 | 30 | 2.5 (1.7-3.6) | <0.001 | 3.1 (1.9-5.0) | <0.001 |
| Primary treatments | ||||||
| Supportive treatments | 126 | 107 | 1 | 1 | ||
| Locoregional therapies | 702 | 413 | 0.2 (0.1-0.2) | <0.001 | 0.2 (0.1-0.2) | <0.001 |
| Surgical resection | 623 | 333 | 0.1 (0.1-0.2) | <0.001 | 0.1 (0.1-0.2) | <0.001 |
| Liver transplant | 34 | 15 | 0.1 (0.1-0.2) | <0.001 | 0.1 (0.1-0.2) | <0.001 |
Events, patient death during follow-up; HR, hazard ratio; CI, confidence interval; BCLC, Barcelona Liver Cancer; CNY, Chinese Yuan (1 CNY≈0.146 USD)